Andromeda Surgical launches autonomous surgery platform for prostate procedures

Overview

Updated Aug 10

For decades, surgical robots have been remote hands: a surgeon moves, the machine copies. Andromeda Surgical wants to change what the machine handles on its own.

The San Francisco startup raised a $15 million Series A and began selling its system, starting with an enlarged-prostate operation called HoLEP. Its software, written partly by engineers who once built self-driving trucks, has helped urologists in three countries treat more than 40 patients.

Why it matters

A steep learning curve keeps HoLEP prostate surgery rare; Andromeda's robot aims to let any urologist perform it at expert level.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$15M

Series A raised

Led by Standard Capital, with Y Combinator and others taking part.

$30M

Total funding to date

Combined across all rounds, per the company.

40+

Patients treated

Across three countries in the ongoing ASTRA clinical study.

30 min

Fastest enucleation time

As fast as 30 minutes, against a published average near 90.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Nick Damiano

Co-founder and CEO, Andromeda Surgical

Leading the commercial launch

Kartik Tiwari

Co-founder and CTO, Andromeda Surgical

Leading engineering

Peter Gilling

Urologist; lead principal investigator, ASTRA trial

Running the clinical study

Organizations Involved

Andromeda Surgical

Medical robotics startup

Just launched commercially

A San Francisco company building AI-guided surgical robots, starting with prostate procedures.

Standard Capital

Venture capital firm

Lead investor in the Series A

The venture firm leading Andromeda's $15 million Series A.

Intuitive Surgical

Medical device company

Incumbent, for context

Maker of the da Vinci robot, the dominant surgical robotics system worldwide.

Timeline

March 2020 August 2026

5 events Latest: August 10th, 2026 · 1 month ago

Tap a bar to jump to that date

August 2026
Andromeda raises $15M and launches
Latest Funding

Andromeda announces a $15 million Series A led by Standard Capital and begins selling its prostate-surgery platform. It reports HoLEP in more than 40 patients across three countries, some as fast as 30 minutes.
August 10th, 2026
July 2025
Johns Hopkins robot removes a gallbladder on its own
Research milestone

A Johns Hopkins robot named SRT-H completes eight autonomous gallbladder removals on lifelike models, adjusting in real time. The work is in the lab, not on live patients.
July 9th, 2025
March 2025
Device-maker partnerships
Business

Andromeda partners with Richard Wolf and Quanta System to widen access to lasers and scopes and speed clinical work abroad. It reports 15 procedures done in Chile and New Zealand.
March 5th, 2025
December 2024
First robotic-assisted HoLEP
Clinical milestone

Dr. Cristián Trucco performs the world's first robotic-assisted HoLEP at Universidad Católica in Santiago, Chile, using Andromeda's tablet interface. The ASTRA clinical trial begins.
December 19th, 2024
March 2020
Starsky Robotics shuts down
Background

The self-driving truck company co-founded by Kartik Tiwari winds down after failing to raise more capital. Much of its software team later moves to surgery.
March 1st, 2020

Scenarios

Andromeda expands ASTRA to 100 or more patients

Likely Resolves by Aug 10, 2027

Discussed by: Andromeda Surgical clinical updates; ASTRA trial disclosures

Andromeda's fastest lever is clinical volume. With partners supplying scopes and lasers and a trial already running in Chile and New Zealand, the company has a clear runway to more cases. Reaching triple-digit patient counts would be the strongest near-term sign the approach travels beyond a handful of expert sites. This is the most likely of the paths here.

Andromeda clears U.S. regulators and enters the American market

Possible Resolves by End of 2027

Discussed by: Medtech trade press (MassDevice, MPO); FDA device-clearance watchers

Andromeda's live cases are abroad. Selling in the United States needs a green light from the Food and Drug Administration (FDA), the agency that decides whether a device is safe to market. The founders' regulatory experience helps, but the FDA has no settled framework for higher surgical autonomy, which can slow first-of-kind systems. A clearance would open the largest surgical market in the world.

Andromeda raises a Series B

Possible Resolves by Aug 10, 2028

Discussed by: Startup funding trackers (Crunchbase); venture press

Hardware plus regulation burns cash. Andromeda has raised $30 million total, enough for early launch but not a global rollout. A Series B would signal that investors believe the clinical data and the commercial pull are real. A long fundraising gap, by contrast, would echo the capital squeeze that ended Tiwari's last autonomy company.

Andromeda runs low on capital before reaching scale

Unlikely Resolves by Aug 10, 2028

Discussed by: Medtech analysts drawing the Starsky Robotics parallel

The downside case is the one the founders know firsthand. Autonomy is expensive and slow to prove, and safety-first companies can run out of runway before the market arrives, which is what happened to Starsky Robotics in 2020. If clinical results stall or funding dries up, Andromeda could wind down, pause operations, or sell for parts. This looks unlikely given fresh funding, but the pattern is real.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2000

da Vinci surgical robot clearance (2000)

U.S. regulators cleared Intuitive Surgical's da Vinci for general laparoscopic surgery. The surgeon sat at a console and the robot copied every hand movement. It decided nothing itself.

Then

Hospitals adopted da Vinci for urology and other procedures, and Intuitive grew into the dominant surgical robotics maker.

Now

Twenty-five years on, mainstream 'robotic surgery' still means a machine that follows a surgeon, not one that acts on its own.

Why this matters now

Andromeda is trying to cross the line da Vinci never did: letting the robot handle steps of the operation, not just mirror the surgeon.

March 2020

Starsky Robotics shutdown (2020)

The self-driving truck company Kartik Tiwari co-founded ran one of the first fully driverless trucks on a public highway in 2019. Months later it shut down, unable to raise more money.

Then

The team dispersed, and its founder wrote a widely read post arguing that safety-first autonomy could not attract enough capital fast enough.

Now

The episode became a reference point for how long and how costly it is to turn autonomy demos into paying business.

Why this matters now

The same founder now leads Andromeda's engineering. His last autonomy venture shows both the technical promise and the funding trap Andromeda must avoid.

October 2023

Cruise robotaxi permit suspension (2023)

California regulators suspended Cruise's driverless permits after one of its cars dragged a pedestrian who had been thrown into its path. Cruise pulled its fleet nationwide.

Then

Cruise lost its California operating license, cut staff, and saw its leadership reshuffled.

Now

The case showed how fast public trust and regulatory approval can vanish for an autonomous system after a single serious incident.

Why this matters now

Surgical autonomy will face the same test. One high-profile failure in an operating room could set back approval and adoption across the field.